You are here

Articles

Dasatinib dose management for the treatment of chronic myeloid leukemia

published: 28 February 2018

Long-Term Outcome Of Nilotinib 400 Mg Twice Daily In First-Line Treatment

published: 27 February 2018

Considerations for Successful Treatment-free Remission

published: 22 February 2018

Pancreatic enzyme elevation in patients treated with nilotinib

published: 20 February 2018

Once a day nilotinib: A Real Life Observational Study

published: 22 December 2017

CAR T Cells: Engineering a patient's immune cells to treat their cancer

published: 2 November 2017

Targeted Antibiotic Use May Help Cure Chronic Myeloid Leukaemia

published: 21 September 2017

In Memoriam: Tessa Holyoake

published: 9 September 2017

Stopping Drug Therapy for CML: EURO-SKI Results

published: 29 July 2017

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

published: 29 July 2017

Striving to vanquish leukaemia: Combination of two compounds shows promise in the lab

published: 20 July 2017

Treatment-free remission following frontline nilotinib in patients with CML in chronic phase: results from the ENESTfreedom study

published: 8 July 2017

Natural Killer Cell Counts Are Associated With Molecular Relapse-Free Survival After Imatinib Discontinuation

published: 10 June 2017

Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy

published: 13 May 2017

Strategies for Stopping TKIs Growing Clearer

published: 2 April 2017

DESTINY: CML Patients With Stable Molecular Responses Safely Halved TKI Dose

published: 8 January 2017

Adding Pioglitazone Could Improve Molecular Response in CML Patients

published: 8 January 2017

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in CML

published: 13 December 2016

Outcomes of the EURO-SKI Trial and the British DESTINY Study Reported ASH Meeting in San Diego Show that Reducing or Stopping a TKI Can Be Safe and Beneficial for Some Patients with CML

published: 8 December 2016

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With CML

published: 15 November 2016